ArticleFrontiers in oncology2022

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial.

Lina Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.